Thermo Fisher Scientific PTGS2 Monoclonal Antibody (OTI6D10), TrueMAB

Applications

• Western Blot (WB): Tested dilution 1:2,000

Product Specifications

Target Information

COX2 converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis, including production of inflammatory prostaglandins. The conversion of arachidonate to prostaglandin H2 is a two-step reaction: a cyclooxygenase (COX) reaction which converts arachidonate to prostaglandin G2 (PGG2), and a peroxidase reaction in which PGG2 is reduced to prostaglandin H2 (PGH2).

COX2 is constitutively expressed in some tissues under physiological conditions, such as the endothelium, kidney, and brain, and is up-regulated under pathological conditions such as cancer and inflammation (in contrast to PTGS1, which is expressed ubiquitously). Up-regulation of COX2 is associated with increased cell adhesion, phenotypic changes, resistance to apoptosis, and tumor angiogenesis.

In cancer cells, COX2 is a key step in the production of prostaglandin E2 (PGE2), which modulates motility, proliferation, and resistance to apoptosis. COX2 is naturally inhibited by calcitriol (active form of Vitamin D). Glucocorticoids chronically trans-repress PTGS2 gene activity in vivo by interfering with transcription initiation and elongation. COX2 is a target of NSAIDs such as aspirin, which reduce pain and swelling from inflammation driven by COX2.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.